<DOC>
	<DOCNO>NCT01666691</DOCNO>
	<brief_summary>The purpose study evaluate weight reduction , safety pharmacokinetics certain dos beloranib ( ZGN-440 injectable suspension ) administer twice-weekly subcutaneous injection 12 week .</brief_summary>
	<brief_title>An Efficacy , Safety Pharmacokinetics Study Beloranib ( ZGN-440 Injectable Suspension ) Obese Subjects</brief_title>
	<detailed_description>This protocol design test safety efficacy drug call beloranib ( ZGN-440 injectable suspension ) . It test ability reduce weight obese subject . The study provide information much ZGN-440 get blood , long stay body , affect biological marker .</detailed_description>
	<criteria>Obese volunteer weigh ≥ 50 kg BMI ≥ 30 ≤ 50 kg/m2 Stable body weight past 2 month Type 2 diabetes mellitus allow Use weight loss agent past month Current , clinically significant eat disorder Type 1 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Obese</keyword>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
	<keyword>Weight loss</keyword>
	<keyword>Weight reduction</keyword>
	<keyword>Beloranib</keyword>
</DOC>